摘要
A771726是免疫调节药来氟米特(leflunomide,LEF)在机体内的活性代谢物,后者在临床上主要用于治疗类风湿关节炎、系统性红斑狼疮、抗移植排斥反应和银屑病。A771726是原形药物,在体内直接吸收起作用,省略了前体药物转化的环节,目前正在申报一类新药。本实验旨在观察其在静脉注射和口服两种给药途径下在大鼠体内肝肠循环的情况,来验证其在体内是否存在肝肠循环,以及发生这种循环的药物占给药量的百分比,了解其在生物体内的代谢转化过程,提供新药临床前研究资料,以支持人体药代动力学研究并为临床用药提供参考依据。
1.生物样品中A771726分析方法的建立
本文采用液液萃取法提取生物样品中A771726,色谱分析采用C18柱,流动相组成为:0.01mol/L甲酸铵缓冲液:甲醇=54.7:45.3;检测波长288nm。采用本文建立的生物样品预处理方法和高效液相色谱法分离测定生物样品中A771726,生物样品预处理回收率高,色谱分离选择性好。本法的准确度、精密度、灵敏度、专属性和定量线性范围均达到了体内药物分析的要求。该方法成功运用于该药在大鼠体内肝肠循环的研究。
2.静脉注射A771726在大鼠体内的药代动力学研究
本部分通过静脉注射给予大鼠A771726,在给药后按时间点采集大鼠血样,利用HPLC分析技术测定各时间点大鼠血浆中A771726的含量,通过运用DAS软件应用统计矩原理求算药动学参数,直读法记录AUC(0-t)、AUC(0-∞)、MRT(0-∞)、Tmax和Cmax,客观地依据原始数据来估算药动学参数。药动学参数如下AUC(0-t):632.53±51.17 mg/L·h ;AUC(0-∞):(2397.774±178.92) mg/L·h;MRT:(38.11±10.77)h;t1/2:(22.23±9.94)h,而配对鼠中的供胆汁组药动学参数为:AUC(0-t):(502.41±29.47)mg/L·h;AUC(0-∞):(1352.85±184.51)mg/L·h;MRT:(24.77±6.17)h;t1/2:(11.94±3.04)h,两组大鼠的药动学参数相比较,发现配对鼠模型中供胆汁大鼠的AUC、MRT、t1/2都比正常组大鼠小,证明了A771726确实存在肝肠循环这一过程。
3.静脉注射A771726在大鼠体内的肝肠循环的研究
运用配对大鼠肝肠循环模型研究A771726在大鼠体内从胆汁重吸收的药动学过程,采用HPLC法测定血浆中A771726浓度,药动学参数用DAS软件统计矩法计算。配对大鼠肝肠循环模型表明,胆汁供体大鼠AUC(0-t):(502.41±29.47)mg/L·h ,AUC(0-∞):(1352.85±184.51)mg/L·h,胆汁受体大鼠的AUC(0-t):(127.28±23.69)AUC(0-∞)(314.94±21.15)mg/L·h。A771726静脉注射后存在肝肠循环现象,约有静脉注射给药量的23.8%进入肝肠循环。
4.口服给药途径A771726肝肠循环研究
实验采用大鼠肝肠循环模型研究口服A771726在大鼠体内肝肠循环情况,用HPLC法测定两组大鼠给药后12 h胆汁及尿液中药物浓度,计算其累积排泄量,药动学参数用DAS软件统计矩法计算。大鼠肝肠循环模型表明, A771726口服后存在肝肠循环现象,约有供体鼠胆汁排泄量的16.88%进入肝肠循环。
A771726 is the active metabolic product of leflunomide the later is a type of immunoregulatory agents.leflunomide educes the pharacological action by metabolized in A771726,and it has been extensively exerted on rheumatoid arthritis,systemic lupus erythematosus,anti-rejection orgn transplantation and psoriasis.A771726 is a active compound,which is directly absorbed in vivo,abbreviate the transformation of prodrug. The works of this paper were designed to investigate the existence of enterohepatic circulation of A771726 and the amount of A771726 involved in this process after intravenous(iv) or intragastric(ig) administration in the rats and investigate the metabolic profile of it,so as to support the pharmacokinetics study in human and offer the reference for clinical dosage and dosage form changing.
Part one:The establishment of analytical method of A771726 in biological matrix A high-performance liquid chromatographic method has been developed for the separation and analysis of A771726 in rats,using a liquid extraction as sample pretreatment for biological matrix.Separation was obtained on a Kromasil C18 column,using an excitation wavelength of 288nm.The chromatographic method used provided good separation and analysis condition.The recovery rate,accuracy rating,precision,saitivity,specificity and the linear range of quantitation of this method all reach the requisition of pharmaceutical analysis.The method has been successfully used to support the study of enterohepatic cycling of A771726 in rats.
Part two: Pharmacokinetics of A771726 in Rats after Intravenous Ad -ministration In this part, A771726 in plasma was determined by HPLC in order to assess the degree of absorption after intravenous(iv) administration in the rats.The pharmacokinetic parameters were estimated with the computer program DAS using non-compartmental analysis.Read the parameters such as AUC(0-t)、AUC(0-∞)、MRT(0-∞)、Tmax and Cmax directly,thus the pharmacokinetic parameters can be objectively estimated based on the original data. The pharmacokinetic parameters were estimated to be AUC(0-t):(632.53±51.17) mg/L·h ;AUC(0-∞):(2397.774±178.92) mg/L·h;MRT:(38.11±10.77)h;t1/2:(22.23±9.94)h, and in the enterhepatic cucling model,the bile-donor group’s pharmacokinetic parameters were estimated to be AUC(0-t):(502.41±29.47)mg/L·h;AUC(0-∞):(1352.85±184.51)mg/L·h;MRT:(24.77±6.17)h;t1/2:(11.94±3.04)h.Compared the two groups of rats’pharmacokinetic parameters,the bile-donor’s parameters were smaller than the normal group’s. This result suggested that enterohepatic cycling of A771726 exist in rats .
Part three: Enterohepatic Cycling of A771726 in Rats after Intravenous Ad -ministration
Rat enterohepatic cycling model was applied to study the process of biliary reabsorption of A771726. Plasma A771726 levels were determined by a HPLC method. The pharmacokinetic parameters were estimated with the soft ware DAS using non-compartmental analysis.In the enterohepatic cycling model, the bile-donor group’s pharmacokinetic parameters were estimated to be AUC(0-t):(502.41±29.47)mg/L·h ,AUC(0-∞):(1352.85±184.51)mg/L·h and the bile-recipient group’s pharmacokinetic parameters were estimated to be AUC(0-t) :( 127.28±23.69),AUC(0-∞):(314.94±21.15)mg/L·h. The findings suggested that enterohepatic cycling of A771726 exist in rats after iv administration. Approximately 23.8% of the intravenous administration dosage enters the enterohepatic circulation.
Part four: Enterohepatic Cycling of A771726 in Rats after Intragastric Administration
Rat enterohepatic cycling model was applied to study the process of biliary reabsorption of of A771726. Bile and urine A771726 levels were determined by a HPLC method. Bile and urine samples were collected within 12 h after ig administration of A771726,and the cumulative percentage of biliary excretion of A771726 in rats was calculated. The findings suggested that enterohepatic cycling of A771726 exist in rats after ig administration. Approximately 16.88% of the bile-donor rats’biliary excretion of A771726 enters the enterohepatic circulation.
引文
1. Bertolini G,Aquino M,Biffi M,et al.Leflunomide,an immunorestoring drug for the therapy of autoimmune disorders,especially rheumatoid arthritis[J].Transplant Proc,1996,28(6):3074-8
2. Pinto P,Dougados M.Leflunomide in clinical practice[J].Acta Reumatol Port.2006,31(3):215-24
3. Chong AS,Finnegan A,Jiang X,et al.Leflunomide,a novel immunosuppressive agent.The mechanism of inhibition of T cell proliferation[J].Transplantation 1993,55(6):1361-66
4. Siemasko KF,Chong A,Williams JW,et al.Regulation of B cell function by the immunosuppressive agent leflunomide[J].Transplantation.1996,61(4):635-42
5. Chong AS,Rezai K,Gebel HM,et al.Effects of Leflunomide and other immunosuppressive agents on T cell proliferation in vitro[J]. Transplantation. 1996,61(1):140-5
6. Paul WE,Seder RA.Lymphocyte responses and cytolines[J].Cell,2004, 76(2): 241-51
7. Weiqman B,jarman ER,Sudowe S,et al.Induction of regulatory T cells by leflunomide in a murine model of contact allergen sensitivity[J].Invest Dermatol.2006,126(7):1524-33
8.梁文权主编.生物药剂学与药代动力学[M].北京
9.彭磊,张茜,金涌,等.来氟米特活性代谢产物A771726在小鼠体内的药动学研究[J].安徽医药,2006,20(10):729-30.
10.姚宏伟,李俊,金涌,等.单剂量口服来氟米特的人体药动学[J].中国药学杂志,2003,38(1):45-7.
11.刘骅,金涌,朱熙,等.A771726在大鼠体内的药代动力学研究[J].安徽医科大学学报,2007,42(2):192-4
12. Gibson GG,Skett P,Introduction to drug metabolism,second edition[M],BlackieAcademic & Professional,an imprint of Chapman & Hall,1996,35
13. Tephly TR,Burchell B.UDP-glucuronosyltransferases a family detoxifying enzymes[J],Trends Pharmacol Sci.1990;11;276-9
14. Kotaki H,Yamamura Y,Tanimura Y,et al,Enterohepatic circulation of cliopinol in the rat[J],J Pharm Dym,1984;7;420-5
15. Tsai TH,Shun AYC,et al,Enterohepatic circulation of chloramphenicol and its glucuronide in the rat by microdialysis using a hepatoduodenal shunt[J],Life Sci,2000;66;363-70
16. Marier JF,Vachon P,Grisa A,et al.Metabolism an diposition of resvertrol in rats:extent of absorption,glucuronidation,and enterohepatic recirculation evidenced by a linked-rat model[J],J Pharmacol Exp Ther,2002;302:369-73
1. SUN Jin,SHI Jie-ming,ZHANG Tian-hong,et al.Impact of release characteristics of sinomenine hydrochloride dosage forms on its pharmacokinetics in beagle dogs[J]. World Journal of Gastroenterology,2005,11(29):4547-4551.
2. HE Zhong-gui, ZHANG Tian-hong,TANG Xing,et al.Preparation and Pharmacokinetic characterization of sustained release melatonin tablet[J].Journal of Chinese Pharmaceutical Sciences,2003,12(2):82-86.
3. CUI Sheng-miao,ZHAO Chun-shun,TANG Xing,et al.Study on the bioavailability of puerarin from pueraria lobata isoflavone self-microemulsifying drug delivery systems and tablets in rabbits by liquid chromatography-mass spectrometry[J].Biomedical Chromatography,2005,19(5):375-378.
4. SUN Jin,ZHANG Tian-hong,QIU Feng,et al.Impact of pharmaceutical dosage forms on the pharmacokinetics of roxithromycin in healthy human volunteers[J].J Antimicrob Chemother,2005,55(5):796-799.
5.Lenner?s H.Human intestinal permeability:an overview[J].J Pharm Sci.1998; 87(4):403-410
6.Lipka E,Spahn-Langguth H,Mutschler E,et al.In vivo non-linear intestinal permeabiliy of celiprolol and propanolol in conscious dogs:evidence for intestinal secretion[J].Eur J Pharm Sci.1998;6:75-81
7.张颖,蒋学华.汉防己甲素大鼠在体肠吸收机制研究[J].中草药,2007,38(2):224-228.
8. Steven C E,Graham L S,Peter J H.Oleuropein,an anti-oxidant polyphenol from olive oil,is poorly absorbed from isolated perfused rat intestine[J].Bethesda,2000,130(12):2996-3002.
9.Mourad FH.Animal and human models for studying effects of drugs On intestinal fluid transport in vivo[J].J Pharmacol Toxicol Methods,2004,50(1):3-12.
10.Menon R M,Barr W H.Comparison of ceftibuten transport across Caco-2 cells andrat jejunum mounted on modified ussing chambers[J] Biopharm Drug Dispos,2003,24:299-308.
11.Mark W W,Gillian F,Gillian C,et a1.Mechanisms of aluminum absorption in rats[J].Am J Clin Nutr,1997,65:1446-1452.
12.唐晓荞,杨祥良.灯盏花素磷脂复合物改善大鼠小肠吸收的研究[J].中国中药杂志,2005,30(3):222-225.
13.王梅,高晓黎.齐墩果酸新型前体脂质体大鼠小肠吸收实验研究[J].新疆医科大学学报,2007,30(2):122-124.
14.计峰,罗绪刚,刘彬,等.用外翻肠囊法研究高钙条件下有机锰在肉仔鸡小肠中的吸收特点[J].中国饲料,2005,15(3):26-30.
15. Prego C,Fabre M,Torres D,et a1.Efficacy and mechanism of action of chitosan nanocapsules for oral peptide delivery[J].Pharm Res,2006,23(3):549-556.
16.Sam M,Linda F,David J B,et a1.Melittin as a Permeability Enhancer-Ⅱ:In vitro investigations in human mucus secreting intestinal monolayers and rat colonic mucosae[J].Pharm Res,2007,24(7):1346-1356.
17.牟永平,吴刚,周立社,等.Caco-2细胞模型在药物研究中的应用[J].中国药理学通报,2005,21(5):536-539.
18.王彦荣,何应.Caco-2细胞模型在天然药物吸收研究中的应用[J].中国生化药物杂志,2007,28(1):66-69.
19. Wijnands WJA, Trooster JEG Teunissen PC, PC, et al. Ciproflocacin does not impair the elimination of diazepam in humans[J]. Drug Metab Dispos.2004;18:954-957.
20. Osbome R, Joel S, Trew D, Slevin M. Morphine and metabolite behavior after different routes of morphine administration of the importance of the active metablite morphine-6-glucuronide[J].Clin Pharmacol Res. 1992;26;317-329.
21. Svensson L. A prodrug approach to a long-actingβ-2 agonist. Drug News Perspect[J].1991;4:544-549.
22. Gunratna C. Drug metabolism and pharmacokinetics in drug discovery:a primer forbioanalytical chemists,part[J].Current Separations.2009;19:17-23.
23. Gibson GG,Skett P,Inrtoduction to drug metabolism,second edition,Blackie Academic & Professional,an imprint of Chapman & Hall[J].1996;35:236-243.
24. Tephly TR,Burchell B.UDP-glucuronosyltransferases: a family of detoxifying enzymes[J].Trends Pharmacol Sci.1990;11:276-279.
25. Kuhnle G,Spencer JP,Chowrinmootoo G,et al.Resveratrol is absorbed in the small intestine as resveratrol glucuronide[J].Biochem Biophys Res Commun.2000; 272: 212-217.
26.Koremer HK, Klotz U.Glucuronidation of drugs[J]. Clin Pharmacokniet. 1992:23: 292-310.
27. Nielsen SE,Dragsted LO.Column-switching HPLC assay of determination apigenin and acacetin in human urine with UV[J].J Chromatogr B Biomed Sci.1998;713:379-386
28. Robert MS,Magnusson BM,Burezynski FJ,et al.Enterohepatic circulation.Clin Pharmacokinet[J].2002;41:751-790.
29. Tsai TH,Shun AY,et al.Enterohepatic circulation of chloramphenicol and its glucuronide in the rat by microdialysis using a hepato-duodenal shunt[J].Life Sci.2000;66:363-370.
30. MarierJF,VaChon P,Gritsas A,et al.Metabolism and disposition of resveratorl in rats:extent of absorption,glucuronidation,and enterohepatic recicrulation evidenced by a linked-rat model[J].J Phamracol Exp Ther.2002;302:369-373.
31.张均田.现代药理实验方法[M].下册.北京:北京医科大学、中国协和医科大学联合出版,1998.1620-36;1663-1668.
32.张金兰,刘颖,周同惠.微透析取样技术在药物代谢研究中的应用及前景[J].药学学报,2001,36(7):555-558.
33.于伟凡.HPLC法测定大鼠肝微粒体温孵体系中奥美拉唑的含量[J].中国医药导刊,2009,11(8):1430-1431.
34.杨哲琼,彭仁琇.精细肝切片技术在药物代谢研究中的应用[J].生物技术,2002,12(2):47-48.
35.徐叔云,卞如濂,陈修.药理实验方法学[M].第2版.北京:人民卫生出版社,488-489.
36. Lupp A,Danz M,Müller D.Morphology and cytoechrome P450 isoforms expression in precision-cut rat liver slices[J].Toxicology,2001,161:53-66.
37. Zamora l,Afzelius L,Cruciani G..Predicting drug metabolism:a site of metabolism prediction tool applied to the cytochrome P450 2C9[J].J Med Chem , 2003 ,46(12):2313-2324.
38.王毅,刘铁汉,王巍,等.肠内菌群对人参皂苷Rg1的代谢转化作用的研究[J].中国中药杂志,2001,26(3):188-1891
39.陈昕,周秋丽,王本祥.人参皂甙Rb1的肠内菌代谢[J].药学学报,1999,34(6):410-414
40.刘铁汉,王毅,王本祥.肠内细菌对淫羊藿苷的代谢转化[J].中草药,2000,31(11):834-837
41.杨肖锋,宋纯清.龙胆苦苷的肠内菌群代谢研究[J].中国中药杂志,2000,25(11):673-676